Efficacy of gefitinib in a patient with lung cancer associated with idiopathic pulmonary fibrosis [4]

Journal of Thoracic Oncology

Volumn 1, Issue 7, 2006, Pages 733-734

  Kishi, Kazuma ^a   Nakata, Koichiro ^b   Yoshimura, Kunihiko ^a  

^a TORANOMON HOSPITAL   (Japan)

^b Nakata Clinic   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GEFITINIB; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

AGED; BRAIN METASTASIS; CANCER REGRESSION; CANCER SIZE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ASSOCIATION; DRUG EFFICACY; FIBROSING ALVEOLITIS; HEMIPLEGIA; HOSPITAL ADMISSION; HUMAN; INFORMED CONSENT; LETTER; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG METASTASIS; MALE; MEDIASTINUM; PRIORITY JOURNAL; RISK FACTOR; THORAX RADIOGRAPHY; TREATMENT OUTCOME; DRUG ANTAGONISM; LUNG FIBROSIS; LUNG NON SMALL CELL CANCER; LUNG TUMOR; LYMPH NODE METASTASIS; METASTASIS;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; PROTEIN KINASE INHIBITORS; PULMONARY FIBROSIS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 34247882039     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/01243894-200609000-00025     Document Type: Letter

References (5)

1. Daniels CE, Jett JR. Does interstitial lung disease predispose to lung cancer? Curr Opin Pulm Med 2005;11:431-437.
2. Thackcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomized, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005;366:1527-1537.
3. Takano T, Ohe Y, Kusumoto M, et al. Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib. Lung Cancer 2004;45:93-104.
4. Hotta K, Kiura K, Tabata M, et al. Interstitial lung disease in Japanese patients with non-small cell lung cancer receiving gefitinib: an analysis of risk factors and treatment outcome in Okayama Lung Cancer Study Group. Cancer J 2005;11:417-424.
5. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-1500.